|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
0.31
billion
|
|
CAGR
(2023-2028)
|
1.68%
|
|
Fastest
Growing Segment
|
Segment
|
|
Largest
Market
|
Northern
& Central
|
Market Overview
Saudi Arabia Human Insulin Market has valued at USD
0.31 billion in 2022 and is anticipated to witness an impressive growth in the
forecast period with a CAGR of 1.68 % through 2028. Human insulin is a peptide
hormone that plays a crucial role in regulating blood sugar levels in the human
body. It is produced by the beta cells of the pancreas, specifically in the
Islets of Langerhans, and is essential for the uptake and utilization of
glucose by the body's cells. Human insulin is a protein hormone composed of 51
amino acids organized into two chains: an A-chain with 21 amino acids and a
B-chain with 30 amino acids. These two chains are held together by disulfide
bonds. Human insulin is synthesized within the pancreas as a precursor molecule
known as proinsulin. Proinsulin is later processed to produce the active
insulin molecule. During this processing, a portion of the proinsulin molecule,
called the C-peptide, is cleaved, and released into the bloodstream along with
the active insulin. The primary role of insulin
is to regulate blood sugar (glucose) levels. It acts as a key that allows
glucose to enter cells, where it can be used for energy production. When blood
sugar levels rise, typically after eating, the pancreas releases insulin to
facilitate the uptake of glucose into cells, thereby reducing blood sugar
levels.
An aging population is more prone to diabetes,
particularly Type II diabetes. As the demographic structure of the country
changes, the market for insulin expands. Urbanization is associated with
lifestyle changes that increase the risk of diabetes. Saudi Arabia's ongoing
urbanization drives the need for diabetes management and insulin therapy.
Greater awareness about the importance of early diabetes diagnosis and
management encourages more people to seek medical care and insulin therapy.
Advances in insulin delivery systems and monitoring technologies improve the
convenience and effectiveness of insulin therapy, encouraging more people to
use insulin. Expanding health insurance coverage and reimbursement policies for
insulin and related supplies can reduce the financial burden on patients and
promote insulin use. Healthcare providers' recommendations and prescriptions of
insulin for diabetes management are a significant driver. The trust and advice
of medical professional’s influence patient choices.
Key Market Drivers
Technological Advancements
Insulin pens have become a popular choice for
insulin delivery due to their ease of use and convenience. These devices offer
accurate dosing, discreetness, and the ability to carry them anywhere. Some
insulin pens are also equipped with memory features, which allow patients and
healthcare providers to track dosages and adherence. Insulin pumps are wearable
devices that continuously deliver insulin, providing a more stable and precise
method of insulin administration. They are programmable and can deliver both
basal and bolus doses, mimicking the body's natural insulin production.
Continuous Glucose Monitoring (CGM) Systems continuously monitor blood glucose
levels and provide real-time data to patients. They allow for better insulin
dose adjustments, reducing the risk of hypoglycemia and hyperglycemia.
Closed-loop systems combine CGM and insulin pump technology to automate insulin
delivery in response to real-time glucose data. This "artificial
pancreas" concept reduces the burden of managing diabetes and improves
glycemic control.
Smart pens are connected devices that record and
transmit dose information to a smartphone app or cloud-based platform. This
technology helps patients and healthcare providers track insulin usage and
adherence over time. Inhalable insulin offers an alternative to injectable
insulin. Patients inhale a dry powder insulin formulation, providing a
non-invasive method of insulin delivery. Long-acting insulin analogs, such as
insulin glargine and insulin detemir, have extended durations of action,
allowing for once-daily or even less frequent dosing. This reduces the need for
multiple daily injections. Researchers are working on developing oral insulin
formulations, which would be easier to administer for some patients. These
formulations need to overcome challenges related to absorption and
effectiveness.
Telemedicine and digital health platforms offer
remote monitoring and consultation for diabetes management. These technologies
provide patients with convenient access to healthcare providers and empower
them to manage their condition more effectively. Advances in biotechnology have
led to the development of biosimilar insulins that are similar in structure and
function to human insulin. These biosimilar insulins can provide cost-effective
alternatives to traditional human insulins. Advancements in genomics and
personalized medicine allow for more individualized diabetes treatment plans,
considering a person's genetic profile, lifestyle, and responsiveness to
different types of insulin. This factor will help in the development of the
Saudi Arabia Human Insulin Market.
Increasing Awareness
Greater awareness about the signs and risk factors
of diabetes encourages individuals to seek medical attention and get screened
for diabetes. Early diagnosis is key to timely intervention and appropriate
treatment, including the use of insulin when necessary. Diabetes prevention
programs often include lifestyle modifications and education on healthy eating
and physical activity. By reducing the incidence of diabetes, these programs
can indirectly limit the demand for insulin. Informed patients are more likely
to actively participate in their healthcare and adhere to prescribed treatment
regimens, including insulin therapy. Knowledge about the importance of insulin
can lead to better self-management of the condition.
Greater awareness can help reduce the stigma
associated with diabetes and insulin use. This, in turn, encourages more
individuals to consider insulin when it is medically indicated. Educated
patients are more likely to understand the benefits of insulin therapy and the
potential risks of non-compliance. They are, therefore, more likely to adhere
to their insulin regimens as prescribed by healthcare providers. Increased
awareness often leads to the formation of patient advocacy groups and support
networks. These organizations can provide valuable information and resources to
individuals with diabetes, further contributing to their understanding and
proactive approach to insulin therapy.
Awareness campaigns target healthcare professionals
as well, ensuring that they are well-informed about the latest guidelines and
recommendations for diabetes management, including the use of insulin when
necessary. Government health departments and agencies may launch public
awareness campaigns as part of their efforts to combat diabetes. These
initiatives can lead to greater recognition of the condition and its
management. Community-based educational programs and events can reach
underserved populations and help them access essential information about
diabetes, insulin therapy, and available resources. This factor will pace up
the demand of the Saudi Arabia Human Insulin Market.
Rising Urbanization
Urban areas often witness significant lifestyle
changes, including sedentary behavior and dietary shifts. These changes can
contribute to an increased risk of developing diabetes, particularly Type 2
diabetes, which may necessitate insulin therapy. Urban populations tend to have
greater access to high-calorie, processed foods that are linked to obesity and
diabetes. These dietary habits can lead to a higher prevalence of diabetes,
increasing the demand for insulin. The demands of urban living can lead to increased
stress, which may have an impact on blood sugar levels. Stress can be a
contributing factor to the development and management of diabetes, potentially
leading to the need for insulin.
Urban environments can expose individuals to higher
levels of air pollution and other environmental factors that have been
associated with an increased risk of diabetes. Urban areas may have limited
opportunities for physical activity, and desk-bound jobs are common. A lack of
physical activity is a risk factor for diabetes, contributing to the need for
insulin therapy in urban populations. Urban areas typically have better access
to healthcare facilities, including clinics and hospitals. This improved access
may lead to more diabetes diagnoses and insulin prescriptions. Urban areas are
often more densely populated, resulting in a higher number of individuals at
risk for diabetes. This increased population density can lead to a larger pool
of potential diabetes patients.
Urban environments are more likely to have greater
access to health awareness and education programs. These programs may encourage
individuals to get screened for diabetes and seek early treatment, which could
include insulin. Urban jobs often involve shift work and irregular schedules,
which can disrupt eating and sleeping patterns. These disruptions can impact
blood sugar control, potentially necessitating insulin therapy. Urban residents
may have greater access to digital devices and screen time, which can
contribute to a more sedentary lifestyle and affect diabetes risk. Urban areas
tend to have a high density of fast-food outlets, which can promote unhealthy
eating habits and obesity, both of which are risk factors for diabetes. This
factor will accelerate the demand of the Saudi Arabia Human Insulin Market.
Download Free Sample Report
Key Market Challenges
Quality and Safety
Ensuring that human insulin products comply with
national and international regulations and quality standards is an ongoing
challenge. Regulatory authorities, such as the Saudi Food and Drug Authority
(SFDA), play a crucial role in monitoring and enforcing these standards.
Counterfeit or substandard insulin products can pose significant safety risks
to patients. Regulators, manufacturers, and distributors need to work together
to combat counterfeit insulin and protect patients. Proper storage and handling
of insulin products are essential to maintaining their quality and safety.
Variations in temperature and mishandling can compromise the effectiveness of
insulin, potentially endangering patients' lives. The insulin supply chain from
manufacturing to patient use is complex and includes multiple stakeholders.
Ensuring the integrity of the supply chain is vital to prevent contamination or
tampering with insulin products. Occasionally, insulin products may need to be
recalled due to quality or safety issues. Managing these recalls and preventing
patient harm is a challenge. Manufacturers must maintain strict quality control
processes throughout the production of insulin. This includes testing the
purity and potency of the insulin to ensure that it meets the required
standards. Monitoring and reporting adverse events associated with insulin use
are essential for identifying safety concerns and taking corrective actions.
Market Competition
Intense competition among pharmaceutical companies
can lead to price pressure. While this can make insulin more affordable for
patients, it may also affect the profitability of insulin manufacturers,
potentially impacting research, and development efforts. To remain competitive,
some manufacturers may cut costs, potentially compromising the quality and
safety of insulin products. Regulatory authorities must ensure that all insulin
products meet stringent quality standards. Gaining and maintaining market share
is challenging. Established insulin manufacturers may face competition from
newer entrants or biosimilar products. This competition can impact their market
share and profitability. Competition encourages companies to innovate and
develop new insulin products. However, keeping up with the latest technological
advancements and staying ahead of competitors can be a significant challenge
for manufacturers. Entering the insulin market is not easy. Manufacturers must
meet regulatory requirements, ensure product quality, and invest in research
and development. These barriers can be challenging for new entrants.
Competition can intensify in the distribution of insulin products. Ensuring
equitable access to insulin across the country, including remote areas, is a
challenge for both manufacturers and distributors.
Key Market Trends
Biopharmaceutical Developments
Biopharmaceutical companies are increasingly
focused on developing insulin products using biotechnological methods. These
products, often referred to as recombinant human insulin or insulin analogs,
are produced through genetic engineering techniques using bacteria, yeast, or
mammalian cells. This results in insulin that closely mimics the structure and
function of human insulin. Biotechnologically derived insulin products tend to
have higher purity and potency compared to insulin extracted from animal sources.
This can result in improved glycemic control and reduced risk of adverse
reactions. Advances in biotechnology have enabled the development of customized
insulin analogs that can better match individual patient needs. These analogs
offer more flexible treatment options, allowing healthcare providers to tailor
insulin therapy to specific patient profiles. Biopharmaceutical developments
have led to the creation of long-acting and ultra-long-acting insulin analogs,
such as insulin glargine and insulin degludec. These insulins provide a basal
level of insulin action for extended periods, reducing the need for multiple
daily injections. Rapid-acting insulin analogs, such as insulin lispro and
insulin aspart, offer faster onset and shorter duration of action, allowing for
better post-meal blood sugar control. The development of biosimilar insulins,
which are highly like existing insulin products, provides more affordable
alternatives for patients while maintaining comparable safety and efficacy.
Segmental Insights
Indication Insights
In 2022, the Saudi Arabia
Human Insulin Market largest share was held by Type Il Diabetes segment and is
predicted to continue expanding over the coming years. Type II diabetes is more
common than Type I diabetes, both globally and in Saudi Arabia. In Type II
diabetes, the body either does not produce enough insulin or is unable to use
it effectively. The higher prevalence of Type II diabetes naturally leads to a
larger market share for insulin used to manage this condition. Type II diabetes
is often associated with factors such as obesity, sedentary lifestyles, and
poor dietary habits. Saudi Arabia, like many countries, has seen an increase in
these risk factors, contributing to the rising prevalence of Type II diabetes.
As populations age, the risk of developing Type II diabetes increases. Saudi
Arabia, like other countries, has experienced a demographic shift with a
growing elderly population, which is more prone to Type II diabetes. There is a
growing emphasis on screening and early detection of Type II diabetes, leading
to more people being diagnosed with this form of diabetes. Early detection
often results in the initiation of insulin therapy, contributing to the demand
for human insulin products. In many cases, individuals with Type II diabetes
initially manage their condition with oral medications. However, as the disease
progresses, some patients may require insulin therapy in combination with oral
drugs. This transition to insulin treatment can boost the demand for human
insulin in the Type II diabetes segment.
Onset Time Insights
In 2022, the Saudi Arabia
Human Insulin Market largest share was held by Intermediate Acting segment and
is predicted to continue expanding over the coming years. Intermediate-acting insulins, such as NPH
(Neutral Protamine Hagedorn) insulin, have a slower onset of action and a more
extended duration compared to rapid-acting insulins. This makes them suitable
for providing a basal level of insulin to manage blood glucose levels
consistently over an extended period. Intermediate-acting insulins are often used
as basal insulin in various insulin regimens. Basal insulin is crucial for
maintaining blood sugar levels between meals and during sleep. Many patients
with diabetes, particularly those with Type 1 and Type 2 diabetes, require a
basal insulin component in their treatment plans. Intermediate-acting insulins
are typically more cost-effective compared to newer long-acting insulin
analogy, which can be important for healthcare systems and patients looking for
affordable treatment options. Intermediate-acting insulins have been available
for many years and are widely accessible in the Saudi Arabia market. Their
availability and familiarity to healthcare providers and patients contribute to
their popularity. The less frequent dosing requirement of intermediate-acting
insulins, typically twice daily, can improve patient compliance compared to
insulins that need more frequent injections.
Products Insights
In 2022, the Saudi
Arabia Human Insulin Market largest share was held by Insulin Pens segment in the forecast
period and is predicted to continue expanding over the coming years. Insulin pens are user-friendly and offer a
convenient way for patients to self-administer insulin. They are particularly
favoured by patients who may have difficulty with traditional insulin vials and
syringes, making them a preferred choice for many people with diabetes. Insulin
pens offer more precise dosing, with clearly marked dose settings, which can be
important in managing diabetes effectively. This precision can lead to improved
diabetes control and better patient outcomes. Insulin pens typically use
smaller, finer needles, which can result in less pain and discomfort during
injections. This can improve patient compliance and overall satisfaction with
insulin therapy. Insulin pens are compact and easy to carry, making them ideal
for individuals who need to administer insulin while on the go. This
portability and convenience are especially valuable for those with busy
lifestyles. Insulin pens can be less stigmatizing compared to traditional
syringes, as they look more like every day writing instruments. This can help
reduce the social barriers and hesitations associated with insulin therapy.
Download Free Sample Report
Regional Insights
The Northern & Central region dominates the
Saudi Arabia Human Insulin Market in
2022. These regions are more densely
populated compared to other parts of the country. A higher population generally
leads to increased demand for healthcare services, including diabetes care and
insulin products. Northern and Central regions often have more developed
healthcare infrastructure, including hospitals, clinics, and specialized
diabetes care centers. This infrastructure facilitates better access to
healthcare services and diabetes management, leading to a higher demand for
insulin. Urban areas in these regions tend to have a higher prevalence of
diabetes due to factors such as sedentary lifestyles and dietary choices. Urban
populations are more likely to require insulin for diabetes management.
Economic activities, including trade, commerce, and industry, are often
concentrated in these regions. This can lead to a higher incidence of diabetes
due to factors such as increased stress and lifestyle changes associated with
urban living. These regions often have better access to healthcare education
and awareness programs, which can lead to earlier diagnosis and treatment of
diabetes. This, in turn, drives the demand for insulin.
Recent Developments
- In July 2022, during a
ceremonial visit with United States of America President Joe Biden, the
leadership of Digital Diagnostics, the creator of IDx-DR, the first-ever
FDA-cleared, fully autonomous AI system for diagnosing diabetic retinopathy,
signed a memorandum of understanding (MOU) with the Ministry of Investment of
the Kingdom of Saudi Arabia. Through this MOU, Digital Diagnostics and the
Kingdom of Saudi Arabia aim to explore potential collaboration in the fields of
medical services, medical technology, and digital health, involving a
significant economic investment. IDx-DR, the product developed by Digital
Diagnostics, streamlines the diabetic eye examination process during the
initial patient encounter, enabling early detection of diabetic retinopathy.
This diabetic eye examination not only enhances patient outcomes but also
results in a lifetime cost savings of $1 million per patient.
Key
Market Players
- Novo Nordisk Saudi Arabia
- Sanofi Saudi Arabia
- Baxter International Saudi
Arabia
- B Braun Saudi Arabia
- Eli Lilly, and Company
Saudi Arabia
- Pfizer Saudi Arabia
|
By
Indication
|
By Type
|
By Onset
Time
|
By Products
|
By Region
|
By Region
|
- Type I Diabetes
- Type Il Diabetes
|
- Basal
- Bolus
- Pre-mixed
- Biosimilar
- Traditional
|
- Rapid Acting
- Short-Acting
- Intermediate
Acting
- Long Acting
- Ultra-long
Acting
- Pre-Mixed
- Inhaled
|
- Insulin Pens
- Insulin
Pumps
- Infusion
System
- Injection
|
- Eastern
- Western
- Northern
& Central
- Southern
|
- Saudi Arabia
- UAE
- Qatar
- Kuwait
- Bahrain
- Rest of
Middle East
|
Report Scope:
In this report, the Saudi Arabia Human Insulin
Market has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Human Insulin Market, By Indication:
o Type I Diabetes
o Type Il Diabetes
- Human Insulin Market, By Route of Administration:
o Subcutaneous
o Nasal
o Intravenous
o Transdermal
o Oral
o Others
- Human Insulin Market, By Type:
o Basal
o Bolus
o Pre-mixed
o Biosimilar
o Traditional
- Human Insulin Market, By Onset Time:
o Rapid Acting
o Short-Acting
o Intermediate Acting
o Long Acting
o Ultra-long Acting
o Pre-Mixed
o Inhaled
- Human Insulin Market, By Products:
o Insulin Pens
o Insulin Pumps
o Infusion System
o Injection
- Human Insulin Market, By region:
o Eastern
o
Western
o
Northern
& Central
o
Southern
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Saudi
Arabia Human Insulin Market.
Available Customizations:
Saudi Arabia Human Insulin Market report with the given market data,
Tech Sci Research offers customizations according to a company's specific
needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Saudi Arabia Human Insulin Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]